Azitra Inc

Azitra Inc’s cutting‑edge skin‑treatments face stark financial headwinds, with a steep stock plunge and negative P/E—investors weigh innovation against losses.

Azitra Inc. secures up to $31.4 M in private placement financing, fueling its precision dermatology pipeline and driving a 55 % share jump.

Azitra Inc, a clinical biopharmaceutical company, is at a crossroads as it navigates financial instability and market skepticism, raising questions about its potential to revolutionize dermatological care.